Pasithea Therapeutics Corp. (KTTAW) Operating Leases (2022 - 2024)

Pasithea Therapeutics has disclosed Operating Leases across 3 years of filings, most recently posting $32989.0 for Q1 2024.

• In Q1 2024, Operating Leases fell 92.91% year-over-year to $32989.0; the TTM figure through Mar 2024 stood at $32989.0 (down 92.91% YoY), while the FY2023 annual figure was $81680.0, down 76.26% from the prior year.
• Operating Leases came in at $32989.0 for Q1 2024 at Pasithea Therapeutics, down from $81680.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $724386.0 in Q3 2022 to a low of $32989.0 in Q1 2024.
• Average Operating Leases over 3 years is $352227.9, with a median of $371766.5 recorded in 2022.
• Year-over-year, Operating Leases grew 18.85% in 2023 and tumbled 92.91% in 2024.
• Over 3 years, Operating Leases stood at $344021.0 in 2022, then tumbled by 76.26% to $81680.0 in 2023, then slumped by 59.61% to $32989.0 in 2024.
• Per Business Quant data, the three most recent Operating Leases figures were $32989.0 in Q1 2024, $81680.0 in Q4 2023, and $385288.0 in Q3 2023.